Triglycomet Tablets

Triglycomet Tablets combine Metformin Hydrochloride (500 mg, sustained release), Pioglitazone (15 mg), and Glibenclamide (5 mg) for effective control of high blood sugar in adults with Type 2 Diabetes Mellitus.

This triple therapy acts by reducing glucose production in the liver, improving insulin sensitivity, and stimulating insulin release — offering comprehensive glycemic management.

Manufacturer: USV Private Limited

• Triple-action control for managing Type 2 Diabetes.
• Helps lower blood glucose and improve insulin utilization.
• Supports long-term glycemic balance and reduces diabetic complications.
• Formulated with Metformin (reduces glucose production), Pioglitazone (improves sensitivity), and Glibenclamide (stimulates insulin release).

• Metformin Hydrochloride I.P. (Sustained Release): 500 mg
• Pioglitazone Hydrochloride I.P. (Equivalent to Pioglitazone): 15 mg
• Glibenclamide I.P.: 5 mg
• Colour: Ferric Oxide Red USP NF
• Excipients: q.s.

As mentioned on the blister: “Each uncoated bilayered tablet contains Metformin 500 mg (SR), Pioglitazone 15 mg, Glibenclamide 5 mg.”

• Use only as directed by your physician.
• Swallow the tablet whole with water — do not crush or chew.
• Best taken with meals to avoid gastrointestinal discomfort.

• Store: Below 30°C in a dry place. Protect from light and moisture.
• Keep away from children and pets.
• Do not use expired or damaged strips.

• Schedule G & H Prescription Drug: To be sold only by retail on the prescription of a Registered Medical Practitioner.
• Consult your doctor if you have liver, kidney, or heart disease before use.
• Patients with bladder cancer or heart failure should use Pioglitazone-containing medicines cautiously.
• Monitor blood glucose regularly and follow dietary recommendations strictly.

Disclaimer: Information provided for educational use only. Follow your doctor’s prescription and advice. Product packaging may vary based on manufacturer updates.